Xilio Therapeutics, Inc.
XLO
Last
$9.05
Day
+0.4%
1y
-23.2%
5y
-96.0%
52w
-28.4%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
9.01
EMA 50
8.99
EMA 200
9.03
20d high
-6.8%
5y high
-97.7%
5y range
1th
Positions held
Your positionsXLO isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
32
Hold
swing
Signal
Strong Buy
Target
$9.01
Stop
$8.62
Stop distance
4.8%
Target vs last
-0.4%
Fundamentals
| Market cap | $59.29M | Enterprise value | -$70.45M | Trailing P/E | — | Forward P/E | -15.53 |
| PEG | — | Price / book | 0.82 | Beta | -0.12 | Dividend yield | 0.00% |
| Revenue growth | 131.2% | Earnings growth | — | Gross margin | 83.2% | Operating margin | -18.7% |
| Profit margin | -34.1% | ROE | -55.0% | ROA | -13.6% | Debt / equity | 0.09 |
| Current ratio | 4.25 | Free cash flow | -$37.56M | Analyst recommendation | none | Mean target | $20.00 |
| 52w high | $12.59 | 52w low | $6.47 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $18.7M | $12.6M | $13.7M | $19.1M | $8.1M | — |
| Op margin | -18.7% | -111.6% | -86.5% | -10.1% | -177.7% | — |
| Net income | -$6.4M | -$9.5M | $10.4M | -$16.3M | -$15.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.5M | -$14.1M | -$11.8M | -$1.9M | -$14.4M | — |
- Revenue +48% vs prior quarter ($19M vs $13M).
- Operating margin expanded to -18.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | $0.0M | $0.0M |
| Op margin | -95.9% | -940.2% | — | — |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$42.0M | -$59.6M | -$79.1M | -$89.1M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-02 · Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-28 · Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
2026-09-02 · Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-12 · Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
2026-07-24 · 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Price (daily)
Full chart · RSI · MACD · patternsXLO · daily-0.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin